Cargando…

Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Detalles Bibliográficos
Autores principales:	Thenappan, Thenappan, Weir, E. Kenneth, Prins, Kurt W, Pritzker, Marc R., Archer, Stephen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483454/ https://www.ncbi.nlm.nih.gov/pubmed/34259020 http://dx.doi.org/10.1161/JAHA.121.021518

Ejemplares similares

Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension Caused by Chronic Lung Disease
por: Prins, Kurt W., et al.
Publicado: (2019)

Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
por: Prins, Kurt W., et al.
Publicado: (2018)

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Sex differences in right ventricular function between Groups 1 and 3 pulmonary hypertension
por: Kazmirczak, Felipe, et al.
Publicado: (2023)

Colchicine Depolymerizes Microtubules, Increases Junctophilin‐2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension
por: Prins, Kurt W., et al.
Publicado: (2017)

Intermittent Fasting Enhances Right Ventricular Function in Preclinical Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Pulmonary Arterial Hypertension and Sex in the Right Ventricle: It Is an Interesting Picture!
por: Thenappan, Thenappan, et al.
Publicado: (2020)

Resistance over compliance describes right ventricular afterload better than resistance-compliance time: a friendly amendment
por: Thenappan, Thenappan, et al.
Publicado: (2017)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension
por: Prins, Kurt W., et al.
Publicado: (2020)

Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2020)

Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension
por: Chang, Kevin Y., et al.
Publicado: (2023)

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis
por: Prins, Kurt W., et al.
Publicado: (2017)

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial Hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2021)

Ingenuity pathway analysis of the human cardiac cell Atlas identifies differences between right and left ventricular cardiomyocytes
por: Prisco, Sasha Z., et al.
Publicado: (2022)

Hemodynamic Characteristics and Outcomes of Pulmonary Hypertension in Patients Undergoing Tricuspid Valve Repair or Replacement
por: Vijayaraghavan, Mahima, et al.
Publicado: (2020)

Ketone bodies in right ventricular failure: A unique therapeutic opportunity
por: Blake, Madelyn, et al.
Publicado: (2023)

Late-onset pulmonary arterial hypertension in repaired D-transposition of great arteries: an uncommon complication
por: Baskaran, Janani, et al.
Publicado: (2017)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Pulmonary hypertension in chronic kidney disease: a hemodynamic characterization
por: Thenappan, Thenappan
Publicado: (2017)

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
por: Thenappan, Thenappan, et al.
Publicado: (2020)

The WHO classification of pulmonary hypertension: A case-based imaging compendium
por: Ryan, John J., et al.
Publicado: (2012)

Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States
por: Chaturvedi, Abhishek, et al.
Publicado: (2020)

Glyoxylase-1 combats dicarbonyl stress and right ventricular dysfunction in rodent pulmonary arterial hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2022)

Diabetes Enters Stage Right: Genetic Association Studies Suggest Diabetes Promotes Pulmonary Hypertension and Right Ventricular Dysfunction
por: Kazmirczak, Felipe, et al.
Publicado: (2023)

Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
por: Chang, Kevin Y., et al.
Publicado: (2022)

Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database
por: Lutsey, Pamela L., et al.
Publicado: (2022)

Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
por: Caputo, Annalisa, et al.
Publicado: (2023)

Pulmonary tumor thrombotic microangiopathy: Exploration into current diagnostic aids and therapeutics
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Beta-blockade improves right ventricular diastolic function in exercising pulmonary arterial hypertension
por: Samaranayake, Chinthaka B., et al.
Publicado: (2023)

Right ventricular dyssynchrony: from load-independent right ventricular function to wall stress in severe pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Evaluation of the Effect of Carvedilol in Preventing Right Ventricular Dysfunction in Breast Cancer Patients Receiving Anthracycline
por: Karvandi, Mersede, et al.
Publicado: (2023)

Pulmonary arterial hypertension and right ventricular systolic dysfunction in COVID-19 survivors
por: Rossi, Rosario, et al.
Publicado: (2022)

Association of right ventricular dysfunction and pulmonary hypertension with adverse 30-day outcomes in COVID-19 patients
por: Wats, Karan, et al.
Publicado: (2021)

Heart Failure Hospitalization Trends During the Early Phase of the COVID 19 Pandemic
por: Fraser, Meg, et al.
Publicado: (2020)

Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension
por: Rain, Silvia, et al.
Publicado: (2014)

Carvedilol in hypertension treatment
por: Stafylas, Panagiotis C, et al.
Publicado: (2008)

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
por: DuBrock, Hilary M., et al.
Publicado: (2021)

External assessment of the EUROMACS right-sided heart failure risk score
por: Shah, Hirak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qilvoa5ligs6jsr5u09b800sec